SAN DIEGO--(BUSINESS WIRE)--May 19, 2004--Hollis-Eden
Pharmaceuticals, Inc. (Nasdaq:HEPH) today announced that it will
present at the UBS 2004 Global Specialty Pharmaceuticals Conference in
New York City, at 9:00 a.m. Eastern (6:00 a.m. Pacific) on Tuesday,
May 25, 2004. Presenting on behalf of the Company will be Daniel D.
Burgess, CFO and COO. A live webcast of the presentation will be
available from the conference. The webcast may be accessed under
"Event Calendar" on the Investors section of Hollis-Eden's website at
www.holliseden.com, and will be archived at the Company's website for
30 days following the presentation.
Hollis-Eden Pharmaceuticals, Inc. is a development-stage
pharmaceutical company based in San Diego, California, working to
become the world leader in the development of a new class of
investigational drugs known as Immune Regulating Hormones (IRHs). The
goal of IRH therapy is to direct, through controlling gene expression,
the production of key cytokines and enzymes that re-regulate immune
and metabolic functions toward homeostasis, a profile that could be
useful in a wide variety of diseases. The Company has a number of
investigational IRHs under development, including NEUMUNE(TM), which
the Company is co-developing with the U.S. military for use in
protection from radiation injury; PHOSPHONOL(TM), a candidate for
providing protection against DNA mutations from radiation exposure and
chemotherapy treatment; and IMMUNITIN(TM), which has shown activity in
a variety of infectious diseases, including HIV/AIDS, tuberculosis and
malaria. Hollis-Eden is also developing IRHs for protection from
chemotherapy and other conditions of immune dysregulation. For more
information on Hollis-Eden, contact the Company's website at
www.holliseden.com.
This press release contains forward-looking statements concerning
the potential and prospects of the Company's drug discovery program
and its drug candidates. Any statement describing a goal, expectation,
intention or belief of the Company is a forward-looking statement and
should be considered an at-risk statement. Such statements are subject
to certain risks and uncertainties, including the failure to
successfully complete clinical trials, the Company's future capital
needs, the Company's ability to obtain additional funding and required
regulatory approvals, the ability of the Company to protect its
intellectual property rights and to not infringe the intellectual
property rights of others, the development of competitive products by
other companies and other risks detailed from time to time in the
Company's filings with the Securities and Exchange Commission. The
actual results may differ materially from those contained in this
press release.
CONTACT: Hollis-Eden Pharmaceuticals
Dan Burgess or Scott Rieger, 858-587-9333
SOURCE: Hollis-Eden Pharmaceuticals, Inc.